NEJM:研究发现亚临床房颤可增加卒中风险

2012-01-20 MedSci 爱唯医学

近日,国际著名杂志The New England Journal of Medicine在线刊登了国外研究人员的最新研究成果“Subclinical Atrial Fibrillation and the Risk of Stroke,”文章中,研究者发现亚临床房颤可增加卒中风险。 大型国际随机ASSERT研究观察到两个重要结果,一是植入起搏器且无临床房颤(AF)史的老年高血压患者较常出现无

近日,国际著名杂志The New England Journal of Medicine在线刊登了国外研究人员的最新研究成果“Subclinical Atrial Fibrillation and the Risk of Stroke,”文章中,研究者发现亚临床房颤可增加卒中风险。

大型国际随机ASSERT研究观察到两个重要结果,一是植入起搏器且无临床房颤(AF)史的老年高血压患者较常出现无症状的AF发作,并且这些亚临床房性快速心律失常与此后缺血性卒中风险骤升有关;二是采用可编程的算法进行连续心房超速起搏以维持心房起搏,既不能预防临床AF,也不能降低卒中风险[N. Engl. J. Med. 2012;366:120-9]。

该研究由加拿大麦克马斯特大学人口健康研究所的Jeff S. Healey博士及其同事进行,共纳入23个国家的2,580例患者。所有患者的年龄≥65岁,均患有高血压,并且近期曾植入双腔起搏器或植入式心律转复除颤器。入组时无1例患者有AF史。在研究开始时,所有植入起搏器的患者被随机分成2组,一组在该时间段内进行连续心房超速起搏,另一组则关闭这一功能。

在随访的最初3个月内,10.1%的患者发生装置检出的亚临床AF(定义为心房率超过190 次/min,并持续6 min以上)。值得注意的是,该亚组患者至发生这种无症状AF的中位时间为36 d,因此,连续数天的阴性Holter动态心电图监测结果可能是假阴性。最初3个月内出现无症状AF的亚组患者在平均2.5年的前瞻性随访期间发生临床 AF的风险增加5.6倍。此外,最初3个月内出现亚临床AF的患者的缺血性卒中或全身性栓塞发生率为1.7%/年,而该研究中其余患者的发生率为 0.69%/年。

在最初3个月内,无症状AF相关卒中或全身性栓塞的人群归因风险(PAR)为13%,这与Framingham 心脏研究观察到的临床AF相关卒中PAR相似。校正卒中标准预测因素的多因素分析显示,最初3个月内装置检出的亚临床AF与此后卒中风险增加2.5倍独立相关,这可能低估了风险的程度,因为该研究中半数以上的患者基线时接受阿司匹林治疗,并且18%出现早期亚临床AF的患者在随访期间接受华法林治疗,这2种药物显然能够有效降低临床AF患者的卒中风险,但尚不清楚它们是否同样对亚临床AF患者有益。

在CHADS2评分大于2且最初3个月内检出亚临床AF的患者中,缺血性卒中或全身性栓塞发生率为3.7%/年,而在CHADS2评分同样较高但无早期亚临床房性快速心律失常的患者中为0.97%/年。除了10%的患者在随访最初3个月内发生亚临床AF之外,还有另外24%的患者在此后发生亚临床 AF。该研究未对持续时间不足6 min的无症状AF发作进行分类,因此不知道这些发作是否也与此后卒中风险增加有关。另外,心房起搏干预并不影响临床AF的发生率,不过该研究对该预后的检验效能不足。

在随刊述评中,西奈山医疗中心内科主任Gervasio Lamas博士指出,尽管该研究明确表明装置检出的亚临床AF与卒中或外周栓塞年发生率增加2倍以上有关,但以下因果关系问题尚有待解决:这些无症状AF 发作是否确实引发心脏栓塞性卒中,或者它们只是可能反映心肌纤维化或结构性心脏病等卒中风险的标志物而已?值得注意的是,在该研究的最初3个月内,最长亚临床AF发作的时间越长,此后的卒中风险越大。在最长发作持续17.7 h以上的患者中,卒中或全身性栓塞的风险增加了近5倍。Lamas博士表示,除非进一步随机临床研究明确证实对装置检出的AF发作时间较短的患者进行抗凝治疗是合理的,否则其仍将继续依赖于CHADS2评分来决定是否对亚临床AF发作持续数小时的患者实施预防性抗凝治疗。

NEJMoa1105575" target=_blank>doi:10.1056/NEJMoa1105575
PMC:
PMID:

Subclinical Atrial Fibrillation and the Risk of Stroke

Jeff S. Healey, M.D., Stuart J. Connolly, M.D., Michael R. Gold, M.D., Carsten W. Israel, M.D., Isabelle C. Van Gelder, M.D., Alessandro Capucci, M.D., C.P. Lau, M.D., Eric Fain, M.D., Sean Yang, M.Sc., Christophe Bailleul, M.D., Carlos A. Morillo, M.D., Mark Carlson, M.D., Ellison Themeles, M.Sc., Elizabeth S. Kaufman, M.D., and Stefan H. Hohnloser, M.D

BACKGROUND One quarter of strokes are of unknown cause, and subclinical atrial fibrillation may be a common etiologic factor. Pacemakers can detect subclinical episodes of rapid atrial rate, which correlate with electrocardiographically documented atrial fibrillation. We evaluated whether subclinical episodes of rapid atrial rate detected by implanted devices were associated with an increased risk of ischemic stroke in patients who did not have other evidence of atrial fibrillation. METHODS We enrolled 2580 patients, 65 years of age or older, with hypertension and no history of atrial fibrillation, in whom a pacemaker or defibrillator had recently been implanted. We monitored the patients for 3 months to detect subclinical atrial tachyarrhythmias (episodes of atrial rate >190 beats per minute for more than 6 minutes) and followed them for a mean of 2.5 years for the primary outcome of ischemic stroke or systemic embolism. Patients with pacemakers were randomly assigned to receive or not to receive continuous atrial overdrive pacing. RESULTS By 3 months, subclinical atrial tachyarrhythmias detected by implanted devices had occurred in 261 patients (10.1%). Subclinical atrial tachyarrhythmias were associated with an increased risk of clinical atrial fibrillation (hazard ratio, 5.56; 95% confidence interval [CI], 3.78 to 8.17; P<0.001) and of ischemic stroke or systemic embolism (hazard ratio, 2.49; 95% CI, 1.28 to 4.85; P=0.007). Of 51 patients who had a primary outcome event, 11 had had subclinical atrial tachyarrhythmias detected by 3 months, and none had had clinical atrial fibrillation by 3 months. The population attributable risk of stroke or systemic embolism associated with subclinical atrial tachyarrhythmias was 13%. Subclinical atrial tachyarrhythmias remained predictive of the primary outcome after adjustment for predictors of stroke (hazard ratio, 2.50; 95% CI, 1.28 to 4.89; P=0.008). Continuous atrial overdrive pacing did not prevent atrial fibrillation. CONCLUSIONS Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, occurred frequently in patients with pacemakers and were associated with a significantly increased risk of ischemic stroke or systemic embolism. (Funded by St. Jude Medical; ASSERT ClinicalTrials.gov number, NCT00256152.)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=37365, encodeId=f11a3e36580, content=Wait, I cannot fathom it being so staotghifrrward., beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=asim, createdTime=Sun Sep 27 07:15:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752944, encodeId=95251e5294422, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 25 18:22:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281136, encodeId=7b721281136c4, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jan 21 15:22:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
    2015-09-27 asim

    Wait, I cannot fathom it being so staotghifrrward.

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=37365, encodeId=f11a3e36580, content=Wait, I cannot fathom it being so staotghifrrward., beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=asim, createdTime=Sun Sep 27 07:15:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752944, encodeId=95251e5294422, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 25 18:22:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281136, encodeId=7b721281136c4, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jan 21 15:22:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=37365, encodeId=f11a3e36580, content=Wait, I cannot fathom it being so staotghifrrward., beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=asim, createdTime=Sun Sep 27 07:15:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752944, encodeId=95251e5294422, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 25 18:22:00 CST 2012, time=2012-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281136, encodeId=7b721281136c4, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jan 21 15:22:00 CST 2012, time=2012-01-21, status=1, ipAttribution=)]

相关资讯

ROCKET AF研究:肾功能不全房颤患者危险高

 8月29日,在欧洲心脏病学会(ESC2011)临床研究更新会上,英国学者Keith A Fox报告的利伐沙班房颤卒中预防(ROCKET AF)随机双盲研究证实,中度肾功能不全的房颤患者卒中和出血的发生率高于正常肾功能房颤患者。在不同治疗剂量组间未发现明显差异。ROCKET AF研究利伐沙班剂量调整治疗的结果与华法林剂量调整治疗比较的总体研究结果一致。  

房颤相关卒中:临床谜题,一一破解

    近期,美国一项研究对世界卫生组织192个成员国的缺血性心脏病(IHD)和卒中数据进行了分析,结果显示,在发展中国家,卒中致死、致残率已高于IHD,中国卒中较IHD死亡率高11.9%,名列第二 [Circulation 2011,124(3):314]。然而,卒中防治是否仅是压在神经内科医生身上的重担?从病因角度进行分析,约20%的卒中归因于心房颤动(房颤),

朱俊:中国房颤卒中预防的现状和未来

房颤患者卒中风险显著增加     房颤是危害人群健康的一种心脏疾病,往往是其他心脏疾病的并发症,也可以作为孤立性房颤存在。我国房颤的发病率及其流行特征与国外数据相似,中国自然人群的房颤患病率为0.6%-0.9%,男女之间没有明显差异,但随年龄的增长,房颤的发生率明显升高,2004年发布的中国心房颤动现状流行病学研究显示,从30岁到80岁以上,随着年龄的增长,房颤患病率

ACC2011:阵发性房颤合并高血压的患者的左心房直径和房颤发生频率

     背景:众所周知,左心房直径(LAD)和房颤的发病率相关。但是,LAD与房颤发生频率的关系仍不得而知。     方法:选取J-RHYTHM II研究中的288名患者,这项随机临床研究的目的是比较CCB和ARB在日本阵发性房颤合并高血压的患者中的治疗效果。LAD的基本结果在心彩超下按标准模式测量得出。在

达比加群治疗房颤1周年 华法林开始走下坡路

数十年来,华法林是临床上预防房颤所致卒中的主要手段,但深受该药使用不便的困扰:合适剂量难以确定而且还在不断变化中,患者需要频繁接受凝血监测,抗凝水平常偏离理想范围而导致卒中或出血并发症增加,此外还需要注意饮食和其他药物以避免发生相互作用。人们都在期待更简便的口服抗凝药物的问世。 第1种替代药物达比加群于2010年10月被美国食品药品管理局(FDA)批准用于房颤患者的卒中预防。1年后的今天,又有2

EHJ:房颤者中断用华法林 血栓栓塞风险升高

 MedSci评论:  华法林作为重要的抗凝药物,以往研究只关注抗凝本身,而很少关注药物中断后的结果。本文立足点相当新颖,临床意义也很重大。同样,其它抗凝药物,也值得我们的思考:利伐沙班,阿哌沙班这类新型抗凝剂,如果中断使用,会不会增加血栓风险?相信,最近两年便会有类似的研究结果出现。我们临床工作者,需要不断从前人的研究结果中反思,寻找新的idea。 12月23日,丹麦